Esperion Therapeutics and Corstasis Therapeutics Announce Esperions Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray)
Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated...